A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Conditions

• Asthma

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Omalizumab — DRUG
  Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.

Study Details

This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.

Key Dates

Start date

Jun 19, 2013

Status verified

Nov 2017

Primary completion

Mar 31, 2016

Completion

Mar 31, 2016

Study Design

Enrollment

806 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Participants With Allergic Asthma
  Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.

Primary Outcome Measure

Total Number of Asthma Exacerbations During Months 1-12 [ Time Frame: Months 1-12 ]

Locations (145)

Find similar trials in Birmingham, AL

Related Studies

• Role of Genetic Factors in the Development of Lung Disease
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
  Recruiting · Gelb, Arthur F., M.D. · Lakewood, California
• Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
  PHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts